PuSH - Publication Server of Helmholtz Zentrum München: Phenolic acids from <em>Anisopus</em> mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Amadi, P.U.* ; Osuoha, J.O.* ; Ekweogu, C.N.* ; Jarad, S.J.* ; Efiong, E.E. ; Odika, P.C.* ; Ejiofor, C.* ; Aloy-Amadi, O.* ; Gill, G.S.* ; Adumekwe, C.W.* ; Gaowa, A.* ; Zhang, D.* ; de Courten, B.* ; Agomuo, E.N.*

Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial.

Pharmacol. Res. 212:107602 (2025)

Publ. Version/Full Text

Research data

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

Phenolic acid-rich fraction from Anisopus mannii (PhAM) contains abundance of ferulic acid, gallic acid, protocatechuic acid, and syringic acid. Among other glycolytic enzymes, in vitro, PhAM counteracted the binding of sodium orthovanadate to phosphofructokinase 1 (PFK-1), improving its activities. In a rat model of diet-induced diabetes, PhAM monotherapy reduced HbA1c by an average of 0.63% and fasting plasma glucose by 25mg/dl. This herb rescued β-cells from streptozotocin-mediated destruction, thereby improving glycemic control. Supported by the preclinical trial, eighty-five patients with type 2 diabetes (T2D) receiving first-line medications were enrolled in a double-blind, randomized, placebo-controlled trial with a 90% power level. Patients were randomized into a placebo group or either of the following two treatment groups: oral administration of 12mg or 20mg/kg body weight of PhAM once every 48h for 6 months. Both treatments were well tolerated. At the endpoint, more than 70% of patients achieved a 0.5 - 2.0 decrease in HbA1c levels and a >20mg/dl decrease in fasting blood glucose, meeting the pre-specified primary outcome. 66% of patients treated with 20mg PhAM achieved the < 7% HbA1c and HOMA-IR of > 1.0 goal. respectively. Our study shows that PhAM can supplement first-line medications to achieve target glycemic control within 6 months. Pan African Clinical Trial Registration number: PACTR202206531545729.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Anisopus Mannii ; Diabetes ; Hba1c ; Phosphofructokinase 1 ; Randomized Trial; Initial Combination Therapy; European Association; Glucose-metabolism; High-fat; Metformin; Mellitus; Insulin; Liver; Mice; Bisleuconothine

ISSN (print) / ISBN 1043-6618

e-ISSN 1096-1186

Journal Pharmacological Research

Quellenangaben Volume: 212, Article Number: 107602

Publisher Elsevier

Publishing Place 24-28 Oval Rd, London Nw1 7dx, England

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Epidemiology (EPI)

Grants Canadian Institute of Health Research
TETF/DESS/POLY/OMUMA/IBR/2023
TETF/ES/POLY/IMO STATE/TSAS/2019
Alborada Foundation
University of Cambridge
TETF/DASTD/UNIV/ OWERRI/TSAS
Tetfund